Durametrix Llc

Durametrix™ is a preclinical contract research organization (CRO) advancing safer, more effective drug development through proprietary, in vivo molecular imaging and expert tissue damage assessment. Founded by scientists with deep expertise in multi-modality imaging (MRI, SPECT, PET, CT, fluorescence), radiochemistry, chemical biology, and drug safety, we specialize in the early detection and characterization of drug-induced tissue injury. Our proprietary imaging platform, TITAN-RX™, enables whole-body, real-time visualization of on- and off-target cytotoxic effects in vivo—non-invasive, dynamic, and quantitative. This capability provides early, system-wide insight into tissue susceptibility and response, long before conventional assays or histopathology can detect damage. We support a wide range of partners—from emerging biotechs and academic researchers to mid-sized and global pharmaceutical companies. All imaging and data analysis are performed fully in-house using standardized, quality-driven workflows that ensure consistency, scientific integrity, and rapid turnaround. Durametrix™ delivers translational imaging and tissue damage insights that bridge discovery and development—empowering drug developers to make smarter, earlier decisions that reduce risk, accelerate timelines, and bring safer therapies to patients faster. Specialties: In Vivo Imaging for Drug Development Drug-Induced Tissue Damage Assessment Translational Safety Biomarkers SPECT/CT, MRI, PET Imaging Radiotracer and Radiopharmaceutical Imaging Preclinical Toxicity Mapping Whole-Body Cytotoxicity Visualization Non-Oncology Safety Evaluation IND-Enabling Study Support Tissue Injury Quantification CRO Imaging Services Molecular Imaging in Drug Discovery Lead Optimization Support Decision-Making Tools for R&D Early Safety De-Risking